Read More

EXCLUSIVE: PainReform Reaches 50% Enrollment Target For Phase 3 Study For Its Lead Postoperative Pain Drug

PainReform hits a 50% enrollment target in the Phase 3 trial for PRF-110 in bunionectomy. No serious adverse events were reported. Over 200 patients enrolled across 8 U.S. sites. CEO Ilan Hadar is optimistic about PRF-110's potential to revolutionize postoperative pain management.

PRFX

Read More

Vertex Announces New Drug Submission For Exagamglogene Autotemcel Has Been Accepted For Priority Review By Health Canada For The Treatment Of Sickle Cell Disease And Transfusion-Dependent Beta Thalassemia

-Exa-cel is the first CRISPR-based gene-edited therapy to be submitted for Health Canada review-TORONTO, April 1, 2024 /CNW/ - Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced its New Drug

VRTX